AngioDynamics Q1 FY2027 results show steady growth in Med Tech

AngioDynamics, a medical technology company focused on vascular health, reported its first quarter results for fiscal year 2027, ending August 31, 2026. The company highlighted continued growth in its Med Tech segment and an adjusted EBITDA positive result, signaling ongoing profitability improvements amid a challenging environment for medical device makers.

What changed in the quarter

The company posted total net sales of $80.9 million for the quarter, up 6.9% year over year. Within that, the Med Tech segment grew by 13.2% to $39.9 million, while the Med Device segment rose 1.4% to $41.0 million. The GAAP gross margin was 59.4%. The company reported a GAAP loss per share of $0.17 but an adjusted loss per share of $0.04, with adjusted EBITDA of $5.0 million. These figures indicate that while overall earnings under standard accounting showed a loss, the company considers its ongoing operations marginally more favorable when excluding certain items.

Key facts and what they mean

Net sales measure total revenue from sales during the quarter. The Med Tech segment includes medical devices and technologies used for vascular health and related care. The Med Device segment reflects another line of devices with a smaller growth rate this quarter. A GAAP gross margin of 59.4% means, under standard accounting rules, the company kept about 59 cents of each dollar of sales after direct costs. An adjusted metric (adjusted EBITDA and adjusted earnings) excludes some non-operational items to show underlying operating performance. A positive Adjusted EBITDA means the core business generated earnings before interest, taxes, depreciation, and amortization in adjusted terms.

Who is affected

Shareholders and potential investors are the primary audience for these results, as they indicate the company’s current profitability trajectory. Employees may be affected by ongoing growth plans and any strategic leadership changes noted, such as the appointment of a new president for a division. The press release mentions leadership changes but does not describe changes in product availability for patients.

Practical next steps for readers

For investors: review the quarter’s detailed financials, including margins and segment performance, and compare with prior quarters to assess momentum. Consider how ongoing cost management and product demand in vascular health could influence future results. For patients or clinicians: no immediate changes to patient care are implied; use the company’s results as context for understanding industry trends in vascular interventional devices and related therapies. If you rely on AngioDynamics products, watch for future updates on product lines or regulatory notices that could affect availability.

Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.